Please use this identifier to cite or link to this item:
|Title:||Frequency and mutational spectrum of PIK3CA gene mutations in breast cancer patients: Largest and first report from Lebanon||Authors:||Hamadeh, Lama N
El Hachem, Georges
El Saghir, Nagi
Gerges, Dany Abi
|Affiliations:||Faculty of Medicine||Keywords:||Breast cancer
|Issue Date:||2023-06-30||Publisher:||Elsevier||Part of:||Gene||Volume:||871||Abstract:||
The PIK3CA pathway is one of the most frequently altered pathways in human cancers, especially in breast cancer with approximately 40% of HR+/HER2- advanced breast cancer cases exhibiting mutations in the PIK3CA gene. While the mutations can occur across the entire gene, the most common are observed in exon 9 corresponding to the helical domain, and in exon 20 encompassing the kinase domain. This study constitutes the first attempt at determining the frequency and mutational spectrum in Lebanese breast cancer patients. For this purpose, DNA samples from 280 breast cancer patients from across Lebanon were screened for PIK3CA mutations using the Therascreen® PIK3CA RGQ Real-time PCR assay. In line with previous reports, 38.57% of cases were positive for at least one PIK3CA mutation, among which approximately 59% were in exon 9 and 37% in exon 20. However, PIK3CA mutations are breast cancer are heterogeneous whereby 20% of known PIK3CA mutants might not be detected by compact PCR based assays. Thus, the adoption of comprehensive Next Generation Sequencing based panels to decipher the complete clinical, molecular and immunohistochemical profile of breast cancer tumor requires further investigation.
|URI:||https://scholarhub.balamand.edu.lb/handle/uob/6807||ISSN:||03781119||DOI:||10.1016/j.gene.2023.147433||Ezproxy URL:||Link to full text||Type:||Journal Article|
|Appears in Collections:||Faculty of Medicine|
Show full item record
checked on Sep 30, 2023
checked on Oct 1, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.